«Vaccine against respiratory
syncytial virus shows promise in early trial: Researchers describe a new approach to developing RSV vaccines, reporting promising early results in young children.»
Not exact matches
The trial was intended to
show that the Novavax vaccine could prevent moderate to severe respiratory
syncytial virus, commonly known as RSV.
A research report published in the Journal of Leukocyte Biology
shows that it may one - day be possible to reduce the incidence of asthma related to infection with respiratory
syncytial virus (RSV).
Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory
syncytial virus (RSV) made with a weakened version of the
virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.